Accutar Biotech

accutarbio.com →

-7%

est. 2Y upside i

HealthcareSeries B

Rank

#2473

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Given the stale valuation, pending litigation, and pre-revenue status, the expected equity upside over 2 years is negative (-7%).

Last updated: July 3, 2026

Bull (10%)+180%

Clinical proof-of-concept for lead candidate drives acquisition by major pharma at 3x current valuation ($3B). IPO window opens, enabling exit at ~$3B.

Base (50%)+30%

Platform development continues with strategic partnerships, valuation appreciates modestly to $1.3B (1.3x) but dilution from required capital raise dampens returns.

Bear (40%)-100%

Lawsuit adversely impacts business development, capital dries up, company is acquired for less than total funding ($207M), common stock worthless.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

21%

Total funding of $207M creates a 1x liquidation preference overhang, representing 21% of the current valuation.

Dilution Risk

high

With no revenue and high burn, a capital raise in 12-18 months is likely, diluting existing common by ~20%.

Secondary Liquidity

none

The last secondary trade was in 2021; no active market exists for pre-IPO shares.

Questions to Ask at the Interview

Strategic questions based on Accutar Biotech's data — designed to show you've done your homework.

  • 1

    “How does Accutar's AI platform differentiate from Recursion and Schrödinger in terms of drug discovery output?”

  • 2

    “What key clinical milestones are expected in the next 12-24 months that could de-risk the pipeline?”

  • 3

    “Given the lawsuit and high cash burn, what is the company's runway and plans for additional financing?”

Community

Valuation Sentiment

Our model estimates -7% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.